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Abstract
Background: Molecular genetic testing is recommended for diagnosis of inherited cardiac disease, to guide prognosis and
treatment, but access is often limited by cost and availability. Recently introduced high-throughput bench-top DNA
sequencing platforms have the potential to overcome these limitations.
Methodology/Principal Findings: We evaluated two next-generation sequencing (NGS) platforms for molecular
diagnostics. The protein-coding regions of six genes associated with inherited arrhythmia syndromes were amplified
from 15 human samples using parallelised multiplex PCR (Access Array, Fluidigm), and sequenced on the MiSeq (Illumina)
and Ion Torrent PGM (Life Technologies). Overall, 97.9% of the target was sequenced adequately for variant calling on the
MiSeq, and 96.8% on the Ion Torrent PGM. Regions missed tended to be of high GC-content, and most were problematic for
both platforms. Variant calling was assessed using 107 variants detected using Sanger sequencing: within adequately
sequenced regions, variant calling on both platforms was highly accurate (Sensitivity: MiSeq 100%, PGM 99.1%. Positive
predictive value: MiSeq 95.9%, PGM 95.5%). At the time of the study the Ion Torrent PGM had a lower capital cost and
individual runs were cheaper and faster. The MiSeq had a higher capacity (requiring fewer runs), with reduced hands-on
time and simpler laboratory workflows. Both provide significant cost and time savings over conventional methods, even
allowing for adjunct Sanger sequencing to validate findings and sequence exons missed by NGS.
Conclusions/Significance: MiSeq and Ion Torrent PGM both provide accurate variant detection as part of a PCR-based
molecular diagnostic workflow, and provide alternative platforms for molecular diagnosis of inherited cardiac conditions.
Though there were performance differences at this throughput, platforms differed primarily in terms of cost, scalability,
protocol stability and ease of use. Compared with current molecular genetic diagnostic tests for inherited cardiac
arrhythmias, these NGS approaches are faster, less expensive, and yet more comprehensive.
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Introduction
Molecular diagnostics are recommended in the management of
inherited diseases, for diagnosis and stratified therapy [1,2,3,4],
but in practice are under-used due to issues of cost, time and
availability of services. Next Generation Sequencing (NGS) DNA
analysis technologies have the potential to overcome these issues
[5]. Inherited cardiac conditions (ICC), such as inherited
arrhythmia syndromes and cardiomyopathies, have been identi-
fied as a suitable area to pilot the development of NGS assays for
clinical use [6,7]. This is due to the relatively high burden of
disease in the population and limitations of current diagnostic
approaches in genetically heterogeneous conditions such as these.
A number of bench-top NGS platforms have recently been
introduced capable of Gigabase-scale DNA sequencing with
relatively short run times (,27 hrs), including the MiSeq
(Illumina) and the Ion Torrent Personal Genome Machine
(PGM; Life Technologies). Initial studies have used these to
characterise genetic targets of clinical significance including;
bacterial genomes [8,9,10,11,12,13,14,15,16], the human breast
cancer BRCA gene [11,17], the cystic fibrosis CFTR gene [18],
HLA type [19] and somatic variation in cancer [20]. The high
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analytical throughput and relative speed make NGS assays very
attractive for early clinical implementation, requiring an in-depth
understanding of the strengths and limitations of each platform in
a clinical diagnostic setting.
A recent study by Loman et al [10] compared bench-top NGS
platforms for sequencing E.coli genomes, which have a GC-content
of 50%, during an outbreak investigation. They identified a higher
rate of homopolymer-associated indel errors in raw reads when
comparing the Ion Torrent PGM to the MiSeq (1.5 and ,0.001
errors per 100 bases, respectively). The MiSeq also detected fewer
single-base substitutions than the Ion Torrent PGM. A further
recent study by Quail et al [8] performed similar analyses using a
number of different bacterial reference genomes representing a
range of GC-contents, including the B.pertussis genome which has a
GC-content of ,68% with some sub-genomic regions .90%.
They observed a higher substitution error rate when using Ion
Torrent PGM than the MiSeq platform (1.78 and 0.4 errors per
100 bases, respectively). Again, they reported fewer homopolymer-
associated errors in MiSeq data than the Ion Torrent PGM. More
variants were called using the Ion Torrent PGM versus MiSeq;
however, this resulted in a slight increase in the number of false
positive calls using the Ion Torrent PGM platform. Both NGS
platforms generated adequate coverage across templates even in
sub-genomic regions of very high GC-content. Significant efforts
to improve sequencing performance and bioinformatics processing
have been undertaken both by the bench-top sequencer manu-
facturers and the NGS community.
In this study, we used microfluidic multiplex PCR and NGS to
sequence six genes that cause inherited arrhythmia syndromes in a
panel of well characterised patient-derived genomic DNAs. We
compared the performance of two bench-top MiSeq and Ion
Torrent PGM DNA sequencing platforms, aiming to develop a
comprehensive pipeline applicable to clinical diagnostics.
Materials and Methods
Human Specimens
The Hammersmith and Queen Charlotte’s & Chelsea Research
Ethics Committee approved the study. DNA was obtained from
subjects who had given written informed consent and was
provided in accordance with Human Tissue Act, UK guidelines.
Fifteen anonymised DNA samples were selected for technical assay
evaluation. Eleven (group I) had undergone mutation scanning of
five Long QT syndrome (LQT) associated genes (See Table 1)
using denaturing high performance liquid chromatography
(dHPLC) [21] coupled with Sanger DNA sequence analysis to
confirm putative variants. Four (group II) underwent exon PCR
amplification and direct Sanger DNA sequence analysis of the full
coding sequence of the same five genes.
Target Enrichment by PCR Capture
Initial Access Array primer design was undertaken by Fluidigm
Corp. (South San Francisco, CA) using the Primer3 oligonucle-
otide design tool [22]. Prior to this study the assay was further
optimized in-house, with additional primers designed to target
regions that were not well captured in pilot studies using the Ion
Torrent PGM [23]. In the final assay 386 amplicons targeted the
protein-coding sequence of six inherited arrhythmia genes
(Table 1), with an overhang at exon boundaries to capture splice
site variants. Figure S1 in the Supporting Information illustrates
the GC-content and length distribution of the 386 Access Array
amplicons.
Genomic DNA templates were amplified using the 48.480
Access Array IFC, according to the manufacturer’s instructions
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(Fluidigm). In brief, each sample DNA was combined with primer
pairs in a microfluidic chip, with a maximum capacity of 48
samples648 10-plex reactions. The chip was loaded with PCR
reagents and transferred to a thermocycler. Common flanking
sequences (CS) on each primer pair permit attachment of
platform-specific barcode indexes and sequencing adaptors in a
subsequent fusion PCR. Pooled amplicons from each DNA
template were harvested and used as input for platform-specific
library preparation.
Platform-specific Barcode/Adapter Attachment
For MiSeq, we followed standard Fluidigm protocols. Ampli-
cons were diluted 1:100 and subjected to a single fusion PCR
reaction using the bidirectional 386 barcode kit, with the FastStart
High Fidelity Enzyme kit (Roche), as per manufacturer’s
instructions. A unidirectional library was prepared for paired-
end sequencing: for each reaction, 1 ml of the diluted harvested
PCR pool was mixed with forward ‘‘A’’ barcodes (indexes 1 to 15,
final concentration 400 nM) and 15ml of PCR pre-mix. Cycling
conditions were as follows: initial incubation at 95uC for 10 min;
15 cycles of 95uC for 15 sec, 60uC for 30 sec and 72uC for 1 min;
final incubation at 72uC for 3 min; hold at 4uC.
For Ion Torrent PGM, commercial barcoding protocols were
not available at the time of the study, so we employed an
equivalent fusion PCR approach using custom oligonucleotides,
yielding a 10 base pair (bp) barcode and Ion Torrent PGM
adaptor (Table S1 in the Supporting Information). The amplicon
harvest volume was adjusted to 20ml using PCR certified water,
and two barcode-fusion PCR reactions were prepared using
opposing CS-tagged primer pairs (e.g. pairing A_BC6_CS1 with
CS2_P1, and A_BC6_CS2 with CS1_P1). This strategy permitted
sequencing of each amplicon in both orientations, in lieu of paired-
end sequencing. For each reaction, 10 ml of the Fluidigm harvest
was added to 86 ml of a Herculase II Fusion PCR mix, as per
manufacturer’s instructions (Agilent Technologies Inc, Santa
Clara, CA) along with 20 pmol each primer. Cycling conditions
were as follows: initial incubation at 98uC for 30 sec; two cycles of
98uC for 30 sec, 54uC for 30 sec and 72uC for 30 sec; final
incubation at 72uC for 2 min; hold at 4uC.
MiSeq Sequencing
MiSeq sequencing was performed at the MRC Clinical Sciences
Centre Genomics Laboratory, Imperial College London, using
MiSeq Reagent kit v1, MCS v1.1.1 and RTA v1.13.56 for
performing image analysis, base calling and quality control (QC).
Ion Torrent PGM Sequencing
Ion torrent PGM sequencing was completed at Royal
Brompton Hospital using Ion One Touch 200 reagents kits
(Release: 20 February 2012, Rev. C), Ion PGM 200 Sequencing
Kit (Release: 21 February 2012, Rev. B) and 316 scale chips.
Sequence analysis was completed with Ion Torrent Suite 2.2
(ITS2.2; Life Technologies) packages. Sequence analysis and
variant calling were subsequently repeated using ITS3.2, but the
results were unchanged, and data from ITS2.2 is presented here.
Bioinformatic Primer Trimming and Read Mapping
Default parameters were used for all data processing and
analysis stages unless otherwise specified. FastQC version 0.9.5
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)
was used to assess sequence quality metrics for each sample,
including per-base and per-sequence quality scores, GC-content,
and read length distribution. Raw sequences generated by MiSeq
and Ion Torrent PGM included primer sequences at both 59 and
39 ends. For MiSeq data, primers were trimmed using an in-
house Perl script, before quality control (average base quality in a
30 bp sliding window .20; 39 read trimming of bases with a
quality score ,6; removal of reads ,20 bp in length) and
alignment with BWA (version 0.6.1-r112-master) [24]. Figure S2
and S3 in the Supporting Information demonstrates the base
quality and length distribution before and after primer trimming
for one sample from MiSeq. Ion Torrent PGM reads were
aligned using ITS2.2, incorporating tmap (version 0.3.7). The
variantCaller plugin module trimmed primers using an aligned
bam file intersected with an amplicon-only bed file. Human
genome reference sequence (hg19) was used for both platforms.
Coverage of the target was assessed using BedTools [25]. The
number of bases covered at sufficient depth and quality for variant
calling was assessed using the Genome Analysis Toolkit (GATK;
version 1.5) [26] Callable Loci Walker. Evenness was calculated
according to the method described by Mokry et al [27] and
implemented with the R statistical package (http://www.r-project.
org). This yielded a score in the range 0–1, with 1 indicating
uniform coverage. Target enrichment factor (EF) was calculated
as, EF~
R=N
T=G
, here R represents the reads on target; N represents
total mapped reads; T represents target size and G represents
genome size [28].
Variant Detection
MiSeq reads were processed using Picard tools (version 1.65,
http://picard.sourceforge.net) and Samtools (version 0.1.18) [29],
and variants were called with GATK. A standard GATK pipeline
was applied including realignment around known indels
(dbSNP135) and recalibration. All reads were used for variant
calling, without downsampling or removal of PCR duplicates.
Variants with QD ,5 or MQ ,30 or DP,30 were filtered out.
For the Ion Torrent PGM, variants were called using the ITS2.2
variantCaller plugin with the Ampliseq and germline workflow.
Primers were trimmed and variants called with a variant frequency
threshold at 25%. The Integrative Genomics Viewer (IGV) [30]
was used for visualization.
Reference Comparator by Sanger DNA Sequencing
Direct dideoxy Sanger DNA sequencing was used to sequence
all protein coding regions of five LQT genes in samples from
group II. Amplicons were prepared using Platinum Taq PCR (Life
Technologies) and GC-Rich PCR system (Roche), and sequenced
using the ABI 3730XL DNA analyzer (Life Technologies).
Though sequenced by NGS, RYR2 was not included in
comparisons as its large size made validation prohibitive. DNA
sequence analysis was performed using Sequencher 4.10.1
(Genecodes Inc, Ann Arbor, MI). Any discordant variant calls
between NGS and dHPLC in group I were also confirmed by
Sanger sequencing. The total number of bases sequenced by the
direct Sanger DNA sequencing method was 61,380 bp.
The sensitivity and positive predictive value (PPV) of variant
detection were calculated by comparing the gold-standard Sanger
data to the NGS data for each platform. 95% confidence intervals
(CI) were calculated using Jeffreys interval, implemented in the
binom package in R.
Results
Sequencing Data Output and Quality
Total sequencing output and mean read lengths from the two
approaches were comparable (Table 2). A single MiSeq run
Molecular Diagnosis of Inherited Conditions
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produced 8.13 million reads (1230 Mb of sequence) as compared
to three 316 chip-scale Ion Torrent PGM runs that generated 6.56
million reads (1001 Mb of sequence). Raw reads generated by
MiSeq have 151 bp fixed length (paired-end read), whilst reads
generated by Ion Torrent PGM had a variable length, using the
200 bp Ion Torrent PGM chemistry kits. The average length of
reads in three Ion Torrent PGM runs was 150 bp (single-end
read).
The two platforms produced a similar yield of filtered sequence
bases. The MiSeq platform produced 95.8% high quality (Q20)
bases and the Ion Torrent PGM 67.5%. As platforms use different
algorithms to estimate base quality, apply different downstream
quality filters and call variants differently [31,32], these raw quality
scores are most useful for comparing runs within platform, and are
provided here for comparison to other datasets. We do not use
these data to compare sequencing performance between plat-
forms. For the MiSeq, raw reads contained primer sequences and
lower quality bases at the 39 ends. Primer trimming and quality
control discarded 4.6% of reads, and excluded 27.6% of bases;
only 18.4% of Q20 bases were excluded, and final trimmed reads
comprised 95.8% Q20 bases. 90.7% of the trimmed reads mapped
to the reference genome, and 96.7% of these mapped reads were
on-target. The average depth of coverage on-target was 1529-fold
(Table 3), with evenness 0.68 and EF 110111.
For the Ion Torrent PGM, reads still contained primer
sequences after de-multiplexing, thus primer trimming was
performed following the alignment procedure. We observed
93.5% raw reads were mapped to the reference genome; 91.2%
of the mapped reads were on-target. The average depth of
coverage on-target was 1231-fold across all samples (Table 3) with
evenness 0.79 and EF 104915. Both evenness and enrichment
factor differed significantly between platforms (p-value
,2.2610216 for evenness and p-value,3.361026 for EF; paired
t-test).
Target Enrichment Performance
Figure 1 summarises the coverage of our genes of interest for
each platform. Overall, 98.8% of the target region was covered by
at least one read for the MiSeq and 98.0% for the Ion Torrent
PGM (Table 4 and Figure S4 in Supporting Information). For
three genes (SCN5A1, KCNE2 and RYR2) coverage consistently
approached 100% on both platforms. KCNQ1 and KCNH2 were
less consistently well covered, averaging 96.2% and 94.1% for
MiSeq, and 93.1% and 88.9% for Ion Torrent PGM, respectively.
While coverage at 16was almost complete for KCNE1, part of the
gene achieved consistently low sequencing depth on the MiSeq
only (see Discussion).
The mean coverage of the protein-coding region of every gene
was consistently .200 reads on both sequencing platforms
(Fig. 1b). The depth of coverage was more consistent between
samples on the MiSeq than on the Ion Torrent PGM (Figure 1b).
By contrast, within-sample coverage was more consistent on the
Ion Torrent PGM (evenness 0.78 vs. 0.68, p,2.2610216; Table 3).
While the MiSeq provided deeper coverage overall, KCNE1 was
an outlier on this platform (Figure 1b), suggesting a platform-
specific sequencing difficulty (See Discussion).
The influence of GC-content on performance was assessed. GC-
content was calculated using a 50 bp sliding window and plotted
alongside sequencing depth across the target for each NGS
platform (KCNQ1 and KCNH2 are shown in Figure 2, remaining
genes in Supporting Information Figure S5). We found that both
platforms performed less well in regions of very high GC-content
(KCNQ1 exons 1 & 8, KCNH2 exons 1, 4, 12, and the 39 portion of
exon 2). The relationship between GC-content and performance
was most reproducible for the Ion Torrent PGM. While the MiSeq
displayed more variability in sequencing depth (See Table 3), the
relationship with GC was weaker suggesting that other factors may
be limiting (Figure S6 in the Supporting Information).
Variant Detection
Variant detection was assessed using a panel of variants
previously identified by dHPLC mutation scanning (group I) or
Sanger sequencing (group II) (Table 5). The majority of known
variants were detected on both platforms, with a small number of
variants missed by each. NGS platforms also detected a number of
variants not previously identified, mainly in samples where
dHPLC rather than Sanger sequencing was used for initial variant
detection. In these samples, validation by Sanger sequencing
confirmed 28/32 (87.5%) unexpected MiSeq variants, and 33/36
(91.7%) Ion Torrent PGM variants (Table 6), which were
therefore dHPLC false negatives. The MiSeq produced four
genuine false positive (FP) SNP calls, and the Ion Torrent PGM
five FPs (four SNPs and one indel), equivalent to positive
predictive values (PPV) of 95.9% (MiSeq; 95% CI 90.5–98.6%)
and 95.4% (PGM; 95% CI 90.3–98.2%).
Variants not detected by NGS were primarily located in regions
without any sequencing coverage. On the MiSeq platform, 14
known variants were not detected (see Table S2 in the Supporting
Information). These included a single common polymorphism in
KCNE1 that was present in 12 samples (chr21:35821821,
Supporting Information Figure S4), and a separate SNP in the
same gene (chr21:35821795). This single exon gene was well
covered by the Ion Torrent PGM, but consistently inadequately
sequenced by the MiSeq across samples, suggesting a platform-
specific, sequence context dependent limitation, rather than a
failure of the upstream PCR capture. The final false negative on
the MiSeq was also missed by the Ion Torrent PGM
(chr7:150645534, KCNH2) in same sample, with no sequencing
reads on either platform at this region of high GC content
(.70%), suggesting that the upstream PCR did not capture this
region. The final variant missed by the Ion Torrent PGM was
found in a well-captured region of KCNQ1 (del at chr11:2594088).
Individual PGM reads contain a high rate of indels in hompolymer
stretches, and the Bayesian calling algorithm has been optimised to
eliminate these when calling variants in the consensus sequence.
Table 2. Comparison of bench-top NGS platforms.
MiSeq Ion Torrent PGM*
NGS runs 1 3
Template preparation 1 hr 365.5 hr
Run time 27 hr 363 hr
Barcodes 15 (commercial) 365 (custom)
Theoretical sequencing output 1.5 Gb 361.27 Gb
Actual sequencing output 1.23 Gb 1.00 Gb
Number of sequencing reads 8.13 M 6.56 M
Read length output 151 150**
Paired-end reads Yes No
Instrument cost $125k $75k
Sequencing cost for assay $959 3x$686
Per specimen sequencing cost $64 $137
*316 scale chip; ** average.
doi:10.1371/journal.pone.0067744.t002
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This true deletion (ACCACCCT -. ACCACCT) resembles such
an error so, while putative variant alleles were detected by ITS, the
variant was rejected as a probable error. This outcome is
insensitive to user-defined filter settings.
Of variants located in sequenced regions, 93/93 (100%; 95% CI
98.0–100%) were detected by MiSeq, and 105/106 (99.1%; 95%
CI 95.7–99.9%) by the Ion Torrent PGM (Table 6). In a
diagnostic setting, the handful of regions of predictable and
consistent low coverage (which harboured the missed variants)
would be targeted with adjunct Sanger sequencing.
The study was not powered to formally compare indel calling,
but 4/4 known indels were detected by MiSeq, and 3/4 by Ion
Torrent PGM with one FP.
Resources and Costs
The MiSeq data was obtained with a single sequencing run, at a
cost of $959 (£609). It required three Ion Torrent PGM runs to
obtain equivalent sequencing output ($686 each) (£439), and one
run was repeated due to low bead deposition on the sequencing
slide. The total sequencing time (from pooled, barcoded sequenc-
ing library to raw sequence data output) was 28 hrs for MiSeq,
including one hour of hands-on time. The equivalent time for each
Ion Torrent PGM run was shorter (9 hrs), but with 4 hrs hands-on
time, as emulsion PCR, enrichment and sequencing occur on
separate machines with human intervention at each stage, whereas
chip loading and cluster generation are automated on the MiSeq
(Table 2).
In summary, PCR-based target enrichment approach followed
by MiSeq and Ion Torrent PGM sequencing interrogated 97.9%
and 96.8% of the target sufficiently for variant detection with
equivalent NGS sequencing output. Variant calling in the regions
covered had a PPV of 95.9% (MiSeq, 95% CI: 90.5–98.6%) and
95.5% (PGM, 95% CI: 90.3–98.2%) with sensitivities of 100%
(MiSeq, 95% CI: 98.0–100%) and 99.1% (PGM, 95% CI: 95.7–
99.9%) (Table 6). In a diagnostic setting, the handful of regions
missed are most likely to require adjunct Sanger sequencing to
achieve up to 100% sensitivity for the assay as a whole.
Discussion
Assay Coverage
Both platforms achieved very good coverage of the target
region. It is unlikely that such an assay will achieve 100%
coverage, largely because GC-rich target is difficult to amplify
using PCR, both at the target enrichment stage and also during
downstream NGS library preparation. We anticipate that for
diagnostic use a small number of regions will continue to require
conventional sequencing approaches, though such a hybrid
Table 3. Sequencing and target capture performance metrics.
Alignment
NGS Platform Reads
Bases
(Mb)
Mean
read
length
Q20
Bases
Mapped
Reads
Reads On
Design
Reads On
Target
Depth On
Target Evenness EF Callable
MiSeq 7757916 889 115 95.8% 90.7% 99.3% 96.7% 1529 68.1% 110111 97.9%
PGM 6133098 969 106 67.5% 100% 96.2% 91.2% 1231 78.8% 104915 96.8%
Mean read length after trimming primer sequences and low quality bases. ReadsOnDesign/ReadsOnTarget = percentage of reads mapping to amplicon design or
protein-coding target region. EF = enrichment factor.
doi:10.1371/journal.pone.0067744.t003
Figure 1. Coverage of target genes. a. The percentage of each gene that is captured and sequenced (at least one read) is shown for each
platform (MiSeq in red, PGM in black), for 15 samples; Three genes were consistently fully sequenced. Coverage of KCNQ1 and KCNH2 was more
variable: KCNQ1 and KCNE1 were fully covered in the best performing samples, while the best performance on KCNH2 covered .97% of the gene. b.
Mean sequencing depth across each gene, for 15 samples. Quartiles are shown. There is significant intra- and inter- sample variability.
doi:10.1371/journal.pone.0067744.g001
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approach still provides for a cost and time saving compared with
conventional sequencing. For the six genes studied here, there are
1256 reported disease-causing variants in this protein-coding
target region [33]; 1217 (96.9%) fall within the regions covered by
the MiSeq, and 1200 (95.5%) by the Ion Torrent PGM.
The Access Array design was iteratively optimized prior to this
study (see Methods). The performance of the manufacturer’s
original amplicon design was assessed, and additional primer pairs
added to the assay to improve the capture of regions that were
under-represented. This pilot work used the Ion Torrent PGM, as
the MiSeq was not available in the UK at that time. This may
marginally favour the Ion Torrent PGM: the MiSeq platform
performed poorly on amplicons derived from KCNE1
(chr21:35821729–35821867, Supporting Information Figures S4
and S5), though these were captured by the Access Array. It may
be possible to produce MiSeq-compatible amplicons with further
iteration tailored to this platform.
These clinically important genes include regions with a very
high GC-content (,80%), such as KCNQ1 exons 1 & 8, KCNH2
exons 1, 4, 12, and the 39 portion of exon 2, which perform
relatively poorly despite optimization efforts. We have previously
found that the performance of some amplicons in the Access Array
can be improved using a GC robust PCR mastermix at this stage,
but these gains are unlikely to persist if non-GC robust enzymes
are used in downstream emulsion PCR during NGS library
preparation. However, as Quail et al were able to successfully
sequence sub-genomic regions with GC-contents.90%, upstream
PCR capture, rather than NGS, is likely to be limiting here, and
this avenue may still yield further improvements.
An alternative upstream target capture technology might also
yield better coverage and hence sensitivity. In this study the
capture methodology was fixed to allow unbiased comparison of
downstream sequencing, but we have previously compared PCR
and hybridisation based approaches for these same gene [34], and
found that overall coverage was very similar for both approaches.
Other studies have reported reproducible patterns of non-uniform
capture across a range of platforms, particular in repetitive
sequences and at extremes of GC content [34,35]. In our opinion
the choice of upstream target capture is most likely to be driven by
cost and capacity requirements: the microfluidic PCR approach
employed here is simple, fast and cheap, but has a much smaller
capacity than hybridisation approaches, for example.
At the throughput employed in this study, both platforms had
significant redundancy of sequencing depth, making them
relatively robust to differences in sequencing depth within and
between samples. If more samples were processed in a single run to
increase throughput, the differences in coverage variability within-
and between- samples may become limiting and influence
platform choice. Inter-sample variability was most marked when
using Ion Torrent PGM, as compared to the MiSeq. Variability
between samples (See Figure 1b) is most likely due to stochastic
error during pipetting and quantification leading to differences in
DNA input at the sequencing stage. In our study there was no
evidence of systematic barcode bias where this could be assessed
on the PGM. Within sample variability is largely reproducible and
sequence-dependent, and is a well-recognized feature of all target
enrichment methodologies [34,36], though sequence-dependent
bias is present even in whole genome sequencing, without target
enrichment.
We acknowledge that we have only studied a small number of
genes here, as the assay was matched to the capacity of a PCR-
based approach, and intended to reflect a typical clinical assay.
Though a range of gene sizes and GC contents were represented,
this may limit the generalizability of findings.
Variant Calling
Variant calling was reassuringly accurate. Sensitivity in the
regions covered by the assay was excellent with just one variant
missed on one platform. Of the four FP SNPs from MiSeq and
four FP SNPs from Ion Torrent PGM, one common error in
KCNH2 exon 5 (chr7:150654468G.A) was called on both
platforms. This site was deeply sequenced with good allele balance
(sequencing depth 2730-fold with 57% alternate reads on MiSeq;
sequencing depth 2403-fold with 55% alternate on PGM), good
mapping quality and variant detection scores from both platforms.
It was the only variant to be discordant between both NGS
platforms and the Sanger method, raising the possibility that it is a
sequence error introduced by upstream PCR. Five out of six
remaining FP SNPs (three MiSeq, two Ion Torrent PGM) were
G.A transitions clustered in KCNH2 exons 12 and 13, and the
final Ion Torrent PGM FP was a G.A transition in SCN5A. Ion
Torrent PGM FPs occurred in regions with good sequencing
depth, but significant strand imbalance and noisy sequencing (high
base quality in individual reads, but poor consensus between
reads). MiSeq FPs were found in areas of relatively low coverage
(,100x), with false alternate allele bases found close to the ends of
the reads, again with strand imbalance.
Importantly, our pipeline included a custom Perl script to trim
poor quality bases at the 39 end of MiSeq reads. This significantly
improved the mapping qualities and reduced the number of false
Table 4. Sequencing coverage of each gene.
MiSeq (%) PGM (%)
1x 10x 20x 30x 50x 100x 1x 10x 20x 30x 50x 100x
KCNE1 98.83 88.77 75.2 69.44 67.64 65.5 100 100 100 100 100 99.81
KCNE2 100 96.42 88.93 85.98 85.98 85.98 100 100 100 100 100 100
KCNH2 94.07 87.66 85.67 84.3 83.22 81.79 88.86 77.91 75.63 74.51 72.95 70.59
KCNQ1 96.22 92.86 89 86.42 79.56 74.03 93.14 86.45 82.68 81.42 80.92 77.39
SCN5A 100 100 99.98 99.69 98.72 95.96 100 100 99.96 99.9 99.75 99.13
RYR2 99.69 97.2 95.16 93.7 90.69 85.78 99.87 99.67 99.65 99.61 99.38 98.86
Overall 98.77 96.14 94.19 92.83 90.3 86.37 97.99 95.98 95.39 95.12 94.72 93.73
The coverage of the protein-coding sequence of each gene of interest is tabulated, as a percentage, for a range of sequencing depths ($1x, 10x, 20x, 30x, 50x and 100x
reads).
doi:10.1371/journal.pone.0067744.t004
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negatives on this platform in our hands (i.e. 9 common variants
were rescued which would have otherwise been missed even with
depth .400). Analysis of raw reads on both platforms showed a
similar substitution mismatch rate (0.5 per 100 bases), with a
higher indel rate in homopolymer stretches on the Ion Torrent
PGM (1.3 vs 0.02 per 100 bases). Nonetheless, final variant calling
accuracy did not differ significantly (odds ratio = 0.90; 95%
confidence interval: 0.24–3.46; p-value = 1; Fisher’s exact test).
This study was not powered to robustly assess differences in indel
detection.
The number of PCR amplification cycles used in the two
methodological approaches differed slightly. The MiSeq method
used 76 PCR amplification cycles, including 26 cycles during
flowcell cluster generation, whereas the Ion Torrent PGM used 82
cycles of PCR amplification, including 45 cycles during emulsion
PCR. Increasing the number of PCR amplification cycles is known
to increase the burden of Taq-related errors [37]. There may be
room to reduce the number of cycles: for example the
manufacturer’s protocol for Illumina library preparation uses a
small aliquot of diluted template from the Access Array, removing
this dilution may allow for fewer PCR cycles.
Current practice in laboratories that are starting to use NGS for
clinical applications is to confirm medically actionable variants
using Sanger sequencing. This study identified a small but
significant number of false positives on both platforms, supporting
this practice.
Cost and Time
Given the strong technical performance of both platforms, issues
of cost and time are likely to be important to laboratories.
Figure 2. Coverage of KCNQ1 and KCNH2 for the two platforms. Mean depth of coverage for 15 samples is shown for two genes on a log
scale. Regions of no coverage therefore have negative values. The blue lines indicate local GC content (calculated with a 50 bp sliding window).
Regions consistently missed have high GC content, with similar patterns for both platforms. KCNQ1 exons 1 & 8 and KCNH2 exons 1, 4 & 12 are
difficult to sequence. A cartoon of the exon structure is shown beneath each panel. Plus (+) and minus (-) denote gene strand. Plots for all genes are
shown in Supporting Information Figure S5. a.) MiSeq b.) Ion Torrent PGM.
doi:10.1371/journal.pone.0067744.g002
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Sequencing capacity and costs change continuously as NGS
platforms evolve, but at present the instrument cost of the MiSeq is
higher than the Ion Torrent PGM. For a single run, the Ion
Torrent PGM was cheaper and faster than the MiSeq, but with
more hands-on time and a higher degree of technical complexity.
With the throughput used in this study, the final cost per sample
was lower for the MiSeq.
The relative youth of the Ion Torrent PGM (UK commercia-
lisation date: mid-2011) means that it is developing rapidly,
offering both advantages and challenges to early adopters.
Challenges have included rapidly changing laboratory and
bioinformatic protocols, reliability issues in our hands, and a
modest per-run capacity at this stage. We readily acknowledge that
performance on each platform is limited by user experience as well
as platform capability, and therefore is likely to continue to
improve. Positive developments include the semi-automation of
emulsion PCR and bead enrichment, with reduced hands-on time,
and the introduction of a larger scale 318-chip, with the potential
to match the data output of the MiSeq in a single run. These
changes may make the Ion Torrent PGM faster and cheaper
overall, though still with more hands-on time than MiSeq. Though
we have piloted the 318-scale chip with satisfactory sequencing
and quality metrics (data not shown), at the time of data collection
for this study we had not yet achieved balanced sequencing of
multiple libraries in order to make use of the increased capacity
and were continuing to use the 316. Subjectively, the MiSeq (UK
commercialisation date: early 2012) has presented a shallower
learning curve, with relatively stable protocols and software
around the study period. When using the MiSeq platform to
sequence low complexity libraries, sequence quality metrics and
the number of reads passing bioinformatic filters are noticeably
worse than those obtained during high-complexity genome
sequencing. Illumina recommend adding 40–50% of a high
complexity target (e.g. phi-X bacteriophage genomic DNA) to low
complexity PCR-generated libraries at the sample loading stage.
This may benefit smaller Access Array-generated libraries, or
libraries with fewer samples in the multiplex. Whilst not used for
this study, this practice would impact on the total useable yield of
the MiSeq platform if widely adopted.
Current diagnostic testing for inherited cardiac arrhythmias in
the United Kingdom is limited to a small number of laboratories,
using exon PCR and direct Sanger sequencing or first-generation
NGS DNA sequencing techniques. We are aware of one UK
centre offering NGS analysis of the 5 LQT genes studied here (plus
KCNJ2) on the Roche 454 GS-FLX sequencer with advertised
turnaround time of 40 working days at a cost of $950 (£600) per
specimen. The 454 currently produces fewer reads than the
desktop sequencers studied here, and the high-throughput target-
enrichment approach that we have employed does not require the
longer read-lengths that are considered one of the principle
advantages of this platform. We conservatively estimate that a
diagnostic workflow using multiplex PCR and desktop NGS takes
20 working days to complete (including variant confirmation by
Sanger sequencing), with likely cost of less than $630 (£400) per
specimen if demand is sufficient to sequence at close to full
capacity (full economic cost including DNA extraction, 15-plex
testing with MiSeq NGS and Sanger variant confirmation studies).
The assay described here also includes the large RYR2 gene that is
associated with another important inherited arrhythmia syndrome,
catecholaminergic polymorphic VT (CPVT). RYR2 is not
currently fully sequenced in available clinical assays in the UK:
testing is limited to ‘‘hotspot’’ exons (UK Genetic Testing
Network, http://www.ukgtn.nhs.uk/, accessed 19th February
2013). A combined assay for LQT & CPVT allows for higher
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assay throughput with reduced cost, and is sensible given the
phenotypic similarity, the small but important number of RYR2
mutations reported in ‘‘genotype-negative’’ LQT cases [38], and
the value of comprehensive genetic testing in molecular autopsy.
In conclusion, we compared two NGS platforms for diagnostic
sequencing. Whilst we do not recommend one platform over
another, both are mature technologies for clinical application, with
the potential to increase availability of molecular diagnostics in
line with national and international recommendations. Perfor-
mance is promising, though sequence-context and platform-
specific biases will influence diagnostic strategies for some genes.
Clinical labs should report the coverage of each gene interrogated
by such an assay and use conventional methods to cover missed
regions and to validate clinically actionable findings. The final
choice of platforms is likely to be governed largely by cost and
usability.
Accession Numbers
Sequence data has been submitted to the European Nucleotide
Archive, accession number ERP002466.
Supporting Information
File S1 ComparisonMiSeq_PGM_supplementary.docx
includes six figures and two tables. Figure S1. Charac-
teristics of target capture design: GC content and length
of Access Array IFC amplicons. a. Amplicon GC content
approximates to a normal distribution 50.3611.4 (%), ,7%
amplicons have extreme (.70% or ,30%) GC-content. b.
Amplicon length (range: 65 bp to 403 bp, median 190 bp and
mean 185629); 85% have a length ,200 bp; 98% amplicons
have sequence length ,240 bp. We used optimised Fluidigm
capture to prepare library for Illumina and Ion Torrent platforms
(see methods). 386 amplicons, with a combined length of
71,915 bp, are tiled over 47,660 bp of target sequence, of which
27,049 bp is protein coding. Figure S2. Base quality
distributions. Sequencing base qualities before (left) and after
(right) trimming and QC from (a.) MiSeq. (b.) Ion Torrent PGM.
The base quality distribution (boxplot at each bar) is plotting
against position in the read; the solid-line curve indicates the
average base quality. Reads from Ion Torrent PGM have better
base quality at 39end as compared to the raw reads generated by
MiSeq. Figure S3.Readlength distribution. The read length
from MiSeq (a) vary from 20 to 135 bp, with average 115 bp626
and median 127 bp; Ion Torrent PGM produced up to 267 bp
reads (b), with average 106 bp657 and median 102 bp. Figure
S4. Coverage of target genes. Here we show the percentage of
each target gene that is covered at $ x sequencing depth,
calculated as a mean across all samples.The lower panels show the
same data, with a larger scale on the x-axis. On the PGM, two
genes (KCNQ1 & KCHN2) show a sharp drop-off in coverage,
suggesting that some regions are difficult to robustly sequence. On
the MiSeq, KCNE1 and KCNE2 also showed significant drop-off.
Figure S5. Sequencing coverage of target genes. Sequenc-
ing depth is plotted for each coding base of the six target genes, on
a log10 scale. Depth is calculated as a mean across 15 samples.
Regions covered by a single read are therefore plotted at the
origin, and regions of zero coverage have a negative deflection on
the y-axis. GC content (calculated with a 50 bp sliding window on
the genomic DNA forward strand) is overlaid in blue. Plus (+) or
minus (-) indicates the strand on which each gene is encoded.
While some regions are clearly problematic for both platforms (e.g.
KCNQ1 exon 2, KCNH2 exons 1 & 12), there are also regions
where one platform performs better (e.g. KCNE1, KCNE2,
KCNH2 exon 4). Figure S6. The relationship between GC
content and coverage. Sequencing depth (log10 scale) for each
exon is plotted against its GC content. The coefficient of variation
is larger for MiSeq than for Ion Torrent PGM (0.931 vs. 0.407).
Loess regression is shown in red. MiSeq performance appears
more variable across the GC range, whereas Ion Torrent
performance falls off at high GC values, perhaps because of the
additional emulsion PCR. Table S1. Barcode indexes and
Ion Torrent specific adapters. Primers used for Ion Torrent
PGM barcoded library prep, with index sequences highlighted.
Each amplicon is inserted into the complex in both orienta-
tions: A-adaptor_Barcode_CommonSequence1_Amplicon_Com-
monSequence2_P1-adaptor; A-adaptor_Barcode_CommonSe-
quence2_Amplicon_CommonSequence1_P1-adaptor. Table S2.
Detected variant information. LRG=Locus Reference
Genomic; Chr =Chromosome; Ref = reference allele; Alt =Alter-
native allele; P =Variants revealed by PGM; M=variants
revealed by Miseq; Highlighted indicates the SNP was missed by
both platforms. Note: All variants appearing in this table were
confirmed by Sanger DNA sequencing analysis.
(DOCX)
Table 6. Accuracy of variant calling for NGS platforms.
Total coding
variants
Variant sites
interrogated
Variants
detected False positives
Variants
missed Sensitivity
Positive predictive
value
MiSeq
Group I 71 60 60 4 0 100% 93.8%
Group II 36 33 33 0 0 100% 100%
Total 107 93 93 4 0 100%
(98.0–100)
95.9%
(90.5–98.6)
PGM
Group I 71 71 71 3 0 100% 96.0%
Group II 36 35 34 2 1 97.1% 94.4%
Total 107 106 105 5 1 99.1%
(95.7–99.9)
95.5%
(90.3–98.2)
Group I: dHPLC with Sanger confirmation; Group II: direct Sanger sequencing 95% confidence intervals are given for sensitivity and positive predictive value.
doi:10.1371/journal.pone.0067744.t006
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